ArticleJournal of medicinal chemistry2020
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 28 citations in OpenAlex.
- In Silico to In Cerebro-Development of the Orexin Receptor Antagonist "Photorexant" for Photomodulation In Vitro and in Mouse Brains.Angewandte Chemie (International ed. in English) · 2026Article
- Is AI Capable of Real-World Drug Discovery?Journal of chemical information and modeling · 2026Article
- Research Progress and Future Perspectives of Orexin Receptor Antagonists in Insomnia Therapy.Molecules (Basel, Switzerland) · 2026Review
- ANNalog: generation of MedChem-similar molecules.Journal of cheminformatics · 2026Article
- Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant.The international journal of neuropsychopharmacology · 2025Review
- Molecular Insights into the Interaction of Orexin 1 Receptor Antagonists: A Comprehensive Study Using Classical and Quantum Computational Methods.Molecules (Basel, Switzerland) · 2025Article
- Cryo-EM structure of an activated GPR4-Gs signaling complex.Nature communications · 2025Article
- Mapping O- and N-Glycosylation in Transmembrane and Interface Regions of Proteins: Insights from a Database Search Study.International journal of molecular sciences · 2025Article
- Heteroaryl derivatives of suvorexant as OX1R selective PET ligand candidates: Cu-mediatedEJNMMI research · 2024Article
- G Protein-Coupled Receptor-Ligand Pose and Functional Class Prediction.International journal of molecular sciences · 2024Article
- Machine learning models to predict ligand binding affinity for the orexin 1 receptor.Artificial intelligence chemistry · 2024Article
- Daridorexant for the treatment of insomnia disorder: findings and implications.European journal of clinical pharmacology · 2022Review
- Antagonization of OXInternational journal of molecular sciences · 2022Article
- Augmented Hill-Climb increases reinforcement learning efficiency for language-based de novo molecule generation.Journal of cheminformatics · 2022Article
- Molecular mechanism of the wake-promoting agent TAK-925.Nature communications · 2022Article
- Modulating Conformational Preferences by Allylic Strain toward Improved Physical Properties and Binding Interactions.ACS omega · 2022Article
- Structural basis of neuropeptide Y signaling through Y1 receptor.Nature communications · 2022Article
- Characteristic structural difference between inactive and active states of orexin 2 receptor determined using molecular dynamics simulations.Biophysical reviews · 2022Review
- Clinical, Genetic and Functional Characterization of a NovelJournal of personalized medicine · 2022Article
- The Novel Application of Geometric Morphometrics with Principal Component Analysis to Existing G Protein-Coupled Receptor (GPCR) Structures.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Mathieu RappasSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Ammar A E AliSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Kirstie A BennettSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Jason D BrownSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Sarah J BucknellSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Miles CongreveSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.ORCID 0000-0003-1913-0318
Robert M CookeSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Gabriella CsekeSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Chris de GraafSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Andrew S DoréSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
James C ErreySosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Ali JazayeriSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Fiona H MarshallSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Jonathan S MasonSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Richard MouldSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Jayesh C PatelSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Benjamin G TehanSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
Malcolm WeirSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
John A ChristopherSosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.ORCID 0000-0001-5737-4650
Granta Design (United Kingdom) · GB
Funding
Discovery of an Orexin-1 receptor antagonist for treatment of cocaine addiction and dependenceR01DA039553 · NIDA · HEPTARES THERAPEUTICS, LTD · PI COOKE, ROBERT · 2015 to 2017
$5.5MNIDA NIH HHS R01 DA039553
Abstract
The orexin system, which consists of the two G protein-coupled receptors OX
Indexed as
Binding SitesComputer SimulationCrystallography, X-RayHEK293 CellsHumansHydrogen BondingHydrophobic and Hydrophilic InteractionsLigandsOrexin Receptor AntagonistsOrexin ReceptorsHCRTR1 protein, humanHCRTR2 protein, humanLigandsOrexin Receptor AntagonistsOrexin Receptors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.